Clinical-stage biotech developing treatments for neurodegenerative disorders.
| Date | Round | Amount |
|---|---|---|
| Nov 2021 | Series B Dutch-Israeli biotech Prilenia Therapeutics raised a USD 43M Series B led by Sands Capital, with Forbion and Morningside. | $43M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.